Back to Agendas
[V5-S6] Industrial Development and Growth Strategy for Biosimilars - From the Viewpoint of the Acceleratation of Biosimilars Use
Session Chair(s)
Teruyo Arato, PhD
Professor, Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Japan
The guidelines for quality/efficacy/safety of biosimilars and its Q and A have been issued in Japan, and currently biosimilar products have been approved in Japan. Expectations for industrial development for biosimilars will be much higher in the future. This session will cover how to change the Japanese medical environment by using biosimilar products and how to accelerate the use of biosimilars, as well as how to the grow industry of biosimilars in Japan. In this session, speakers from a pharmaceutical industry and academia will give a presentation about current environment and issues of the acceleration of biosimilars use. We will have a panel discussion with the above speakers and a panelist from a department of pharmacy in a hospital, who will talk about biosimilars use in a pharmacy point of view.
Speaker(s)
Tetsuji Tsukamoto, MBA
Head of Pharmaceutical Development Division,Pharmaceuticals Development Division, Nippon Kayaku Co., Ltd., Japan
Launching Experiences of Biosimilars and Issues for Wider Use
Sreedhar Sagi, PhD
Head Medical Affairs, APAC, Sandoz Biopharmaceuticals, Germany
Biosimilar: Learnings from Nearly 10 Years of Real World Experience
Yasuo Terauchi, MD, PhD
Professor, Endocrinology & Metabolism, Graduate School of Medicine, Yokohama City University, Japan
Expectation for Biosimilar Insulin Products by Clinical Diabetologists
Keiso Masuhara
Department of Pharmacy, St. Marianna University School of Medicine Hospital, Japan
Have an account?